The Goals of the Tissue Acquisition, Prcoessing and Pathology Core are: A. Review and analyze pathologic specimens from clinical trial patients (with Project 1), including expression of mesothelin levels and potentially other tumor antigens. B. Process and archive clinical specimens from ongoing and planned clinical trials (with Project 1). C Perform assays for Interferon-alpha, anti-adenoviral neutralizing antibodies, serum mesothelin, and antitumor antibodies (with Project 1) D. Tissue acquisition (with Projects 1, 2 and 3). E. Establish stable cell lines from tumors derived from clinical trial subjects and other surgical patients (with Projects 1, 2, and 3). F. Assist in immunohistochemical analyses Dr. Michael Kalos will be the Director of the TAPP Core due to the unfortunate death of Dr. Carroll. Dr. Leslie Litzky, a Board-Certified Anatomic Pathologist, will focus on goal A and continue in her previous role as the designated reference pathologist for confirmation of diagnosis prior to patient enrollment in clinical trials and review of mesothelin or other antigen expression on tumor samples. Dr. Steven Albelda who has the expertise needed to perform revised Goals C (previously established serological assays) and E (cell line establishment) will assist in this core.

Public Health Relevance

The TAPP core will support all 3 projects by providing important sen/ices including review of pathological specimens, specimen handling, biomarker assays, tissue acquistion, and immunohistochemical studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47
Sterman, Daniel H; Alley, Evan; Stevenson, James P et al. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. Clin Cancer Res 22:3791-800
O'Hara, Mark; Stashwick, Caitlin; Haas, Andrew R et al. (2016) Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8:449-60
Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90
Liu, X; Barrett, D M; Jiang, S et al. (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430
Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51
Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi et al. (2015) Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res 3:815-26
Frigault, Matthew J; Lee, Jihyun; Basil, Maria Ciocca et al. (2015) Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3:356-67
Lo, Albert; Wang, Liang-Chuan S; Scholler, John et al. (2015) Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res 75:2800-10
Liu, Xiaojun; Jiang, Shuguang; Fang, Chongyun et al. (2015) Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res 75:3596-607

Showing the most recent 10 out of 82 publications